Sites Menu > APS - Opthalmology Related


APS - Opthalmology Related


Ophthalmic signs in antiphospholipid syndrome. Patient description

Klin Oczna. 2004;106(4-5):661-3 CONCLUSIONS: presented characteristic general and ophthalmic signs point to APS.

Retinal vein occlusion in two patients with primary antiphospholipid syndrome.

Korean J Intern Med. 2001 Dec;16(4):274-6

Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment.

Clin Experiment Ophthalmol. 2004 Feb;32(1):87-100 Conclusion: Severe vaso-occlusive retinopathy is a rare form of retinopathy in SLE often associated with poor visual prognosis and neovascularization. It may be a manifestation of the antiphospholipid syndrome. Treatment is aimed at preventing further thrombosis and complications arising from neovascularization.

Handbook of Ocular Disease Management Antiphospholipid Syndrome

Patients with antiphospholipid antibody syndrome (APAS) tend to be under age 50 and female. Up to 2% of women may have antiphospholipid antibodies. Many will also have lupus or other autoimmune diseases.

Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy.

Am J Ophthalmol. 1997 Jun;123(6):848-50 CONCLUSIONS: In retinal vascular occlusions of unexplained origin, antiphospholipid antibodies may play an important role in the pathogenesis. Detecting these antibodies in the serum of patients with retinal vascular occlusion helps determine the appropriate treatment with long-term oral anticoagulants.

Sudden painless unilateral vision loss caused by branch retinal artery occlusion: implications for the primary care physician.

Am J Med Sci. 2004 Jan;327(1):44-6

Central retinal venous occlusion with co-existent thrombotic thrombocytopenic purpura and antiphospholipid syndrome

British Journal of Ophthalmology 2003;87:658-659 © 2003 BMJ Publishing Group

Visual disturbances and pathologic ocular findings in primary antiphospholipid syndrome.

Ophthalmology. 1999 Aug;106(8):1537-40 CONCLUSIONS: Ocular involvement in PAS is uncommon. Transient visual disturbances are common, although most of them are related to central nervous system rather than ocular ischemia. Pathologic ophthalmic findings are unlikely to be found in asymptomatic patients or in patients with transient visual disturbances. Routine retinal fluoroangiography performed on patients with PAS is unproductive.

Ocular symptoms in association with antiphospholipid antibodies.

Graefes Arch Clin Exp Ophthalmol. 1998 Sep;236(9):658-68 CONCLUSIONS: We did not find a clear correlation between APA activity or the immunoglobulin classes in the individual and the severity of the ocular disease. The benefit from a therapy with the antiplatelet agent acetylsalicylic acid was evident in a reduction of the patients' transient visual disturbances and, in most cases, no further progression of permanent visual field defects was observed.

Bilateral retinal vascular occlusion during antiphospholipid antibody syndrome: a case report

J Fr Ophtalmol. 2005 May;28(5):503-7 DISCUSSION AND CONCLUSION: Central retinal artery or vein occlusion in a young patient must suggest the diagnosis of antiphospholipid antibody syndrome. The bilateralism of vascular occlusion is considered a severe factor because of its consequence on functional ocular and vital prognosis, where it can sound the alarm to the extension of thrombotic events to other vessels in the body. Antiphospholipid syndrome must be studied in cases of severe retinal vascular occlusion in young patients. Its diagnosis is important because the risk of recurrent thrombotic events may endanger functional and vital prognosis.





 

 

The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2016 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295